117 related articles for article (PubMed ID: 1810439)
21. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
22. Local interleukin-2 and interleukin-12 therapy of bovine ocular squamous cell carcinomas.
Stewart RJ; Masztalerz A; Jacobs JJ; Den Otter W
Vet Immunol Immunopathol; 2005 Jul; 106(3-4):277-84. PubMed ID: 15963825
[TBL] [Abstract][Full Text] [Related]
23. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic potential of biological response modifiers against transplantable mouse tumors of spontaneous origin. II. Local interleukin 2 treatment of tumors of different immunogenic strength.
Fiszer-Maliszewska L; Den Otter W; Madej JA; Mordarski M
Arch Immunol Ther Exp (Warsz); 1998; 46(5):293-300. PubMed ID: 9832068
[TBL] [Abstract][Full Text] [Related]
25. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
26. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2.
Vallera DA; Taylor PA; Aukerman SL; Blazar BR
Cancer Res; 1993 Sep; 53(18):4273-80. PubMed ID: 8364923
[TBL] [Abstract][Full Text] [Related]
27. [The anti-tumor efficacy of human recombinant interleukin-2 (rIL-2) in vivo].
Wang C; Chai L; Zhu G
Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):27-9. PubMed ID: 7656782
[TBL] [Abstract][Full Text] [Related]
28. In vivo antitumor activity of anti-CD3-induced activated killer cells.
Yun YS; Hargrove ME; Ting CC
Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
[TBL] [Abstract][Full Text] [Related]
29. Isolation and characterization of a metastatic Eb-like tumor variant highly responsive to interleukin (IL)-2 and to combination cytokine therapy with IL-2/IL-1 beta and IL-1 beta/interferon-alpha/beta.
Gabriele L; Proietti E; Greco G; Venditti M; Gresser I; Schirrmacher V; Von Hoegen P; Testa U; Modesti A; Cianfriglia M
Invasion Metastasis; 1993; 13(3):147-62. PubMed ID: 8112975
[TBL] [Abstract][Full Text] [Related]
30. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
Silagi S; Schaefer AE
J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy of the SL2-5 murine lymphoma with natural killer cells and tamoxifen or toremifene.
Baral E; Nagy E; Kangas L; Berczi I
Anticancer Res; 1997; 17(1A):77-83. PubMed ID: 9066633
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
Eggermont AM; Sugarbaker PH
Cancer Detect Prev; 1990; 14(4):483-90. PubMed ID: 2224911
[TBL] [Abstract][Full Text] [Related]
33. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
[TBL] [Abstract][Full Text] [Related]
34. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice.
Gately MK; Anderson TD; Hayes TJ
J Immunol; 1988 Jul; 141(1):189-200. PubMed ID: 3259967
[TBL] [Abstract][Full Text] [Related]
35. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
Donohue JH; Rosenstein M; Chang AE; Lotze MT; Robb RJ; Rosenberg SA
J Immunol; 1984 Apr; 132(4):2123-8. PubMed ID: 6607956
[TBL] [Abstract][Full Text] [Related]
36. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
37. Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma.
Ho RL; Maccubbin DL; Ujházy P; Zaleskis G; Eppolito C; Mihich E; Ehrke MJ
Oncol Res; 1993; 5(9):363-72. PubMed ID: 8038457
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of murine hepatic metastases with lymphokine-activated killer cells expanded in serum-free media and recombinant interleukin 2.
Lafreniere R; Borkenhagen K; Bryant LD; Huchcroft S
Cancer Res; 1989 May; 49(9):2409-14. PubMed ID: 2565160
[TBL] [Abstract][Full Text] [Related]
39. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
Thompson JA; Peace DJ; Klarnet JP; Kern DE; Greenberg PD; Cheever MA
J Immunol; 1986 Dec; 137(11):3675-80. PubMed ID: 3491145
[TBL] [Abstract][Full Text] [Related]
40. Effect of combined adoptive immunotherapy and radiotherapy on tumor growth.
Sumareva R; Ukrainsky G; Kiremidjian-Schumacher L; Roy M; Wishe HI; Steinfeld AD; Cooper JS
Radiat Oncol Investig; 1999; 7(1):22-9. PubMed ID: 10030620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]